https://www.live-feeds.com/feed/iovance-stock-falls-after-lung-cancer-trial-data-disappointsContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/iovance-stock-falls-after-lung-cancer-trial-data-disappointshttps://www.live-feeds.com/feed/iovance-stock-falls-after-lung-cancer-trial-data-disappoints#u174300Wed, 04 Nov 2026 13:31:09 +0000Shares of Iovance Biotherapeutics plummeted after the company released updated clinical trial results for its cancer therapy, lifileucel. The stock initially crashed sharply before settling into a steep multi-day decline, losing over 35 percent in a single session. Financial institutions responded by lowering price targets on the equity. The selloff was triggered by updated findings from cohorts in a mid-stage trial evaluating the treatment in previously treated lung cancer patients, prompting investor concern despite the presence of certain encouraging subgroup results.Why it mattersThe sharp